GlobeNewswire

BroadSoft Named to the Constellation ShortList(TM) for Enterprise Group Messaging

Dela

BroadSoft Business UC-One® App Honored as One of Seven Enterprise Group Messaging Solutions

GAITHERSBURG, Md., Aug.  09, 2017  (GLOBE NEWSWIRE) -- BroadSoft, Inc. (NASDAQ:BSFT), a global market leader in cloud business software for cloud PBX, unified communication, and provider of team collaboration and contact center as a service (CCaaS), today announced that BroadSoft Business UC-One ® application is included in the Constellation ShortList(TM) for enterprise group messaging solutions in Q3 2017. The Constellation ShortList(TM) presents vendors in different categories of the market relevant to early adopters. Inclusion signifies BroadSoft as a leading provider of messaging tools in the market and its influence on the way people expect to be able to communicate at work.

"We are pleased that the UC-One application has been identified by Constellation as a leader in the enterprise messaging industry yet again," said Taher Behbehani, chief digital and marketing officer, BroadSoft. "As the future of work continues to advance, we believe that our BroadSoft Business portfolio of cloud communications and team collaboration solutions will continue to unlock greater productivity for our customers as their employees connect, communicate and collaborate across channels."

Constellation advises leaders and teams on leveraging disruptive technologies to achieve business model transformation. Products and services named to the Constellation ShortList meet the threshold criteria for this category as determined by Constellation Research through client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research.  The Constellation ShortList is frequently updated as market conditions change.

"The right timing, teams and technology are the three Ts for crafting digital business models to achieve digital transformation success," said R "Ray" Wang, chairman and founder at Constellation Research. "Each Constellation ShortList, researched and curated by our analysts, guides early adopters in identifying the right technologies to build successful and competitive programs."

UC-One is an application from the BroadSoft Business portfolio that provides integrated business phone services, messaging and presence, audio and video conferencing, screen sharing, file sharing, virtual meeting rooms and more. The solution provides advanced mobile-first cloud unified communication for businesses of all sizes. Users can communicate and collaborate with colleagues, partners, and customers regardless of location or device. BroadSoft Business is a fully integrated portfolio of enterprise-ready cloud unified communications, team collaboration and contact center applications, delivered in the cloud.

Find out more about BroadSoft UC-One, unified communication and team collaboration solution here.

About BroadSoft

BroadSoft is the technology innovator in cloud PBX, unified communications, team collaboration, and contact center solutions for businesses and service providers across 80 countries. We are the market share leader for cloud unified communications with an open, mobile and secure platform trusted by 25 of the world's top 30 service providers by revenue. Our BroadSoft Business application suite empowers users and teams to share ideas and work simply to achieve breakthrough performance. For additional information, visit www.BroadSoft.com.

Twitter | LinkedIn | BroadSoft Blog

Disclaimer
Constellation Research does not endorse any solution or service named in its research.

About Constellation Research
Constellation Research is an award-winning, Silicon Valley-based strategic advisory and futurist research firm. Constellation's analysts serve as innovation advisors for leaders and Global 2000 organizations navigating the challenges of business-model disruption and transformation. Unlike legacy analyst firms, Constellation works closely with solution providers, partners, and its Constellation Executive Network of innovative buy-side leaders, C-suite executives and board of directors to lead the way in disrupting technology and research coverage areas. The goal - deliver to clients what they need to achieve valuable business results.

For more information about Constellation Research, visit www.ConstellationR.com.

Matter for BroadSoft
Erin Knapp
Matter
617-502-6546
broadsoft@matternow.com

BroadSoft
Niaobh (Neve) Levestam
BroadSoft
+44 7919 605660
nlevestam@broadsoft.com

Constellation Research
Aubrey Coggins
Press@Constellationr.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BroadSoft, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum